-- Substudy promptly accrued 36 patients in less than six months, with majority of newly enrolled patients receiving low-dose steroids -- BOSTON , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that it rapidly completed enrollment and treated a total of 36
BOSTON, MA, January 10, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) Laurence Cooper, M.D., Ph.D., Chief Executive Officer, today is presenting at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco at 9 a.m. PT/12 noon ET.
BOSTON , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today posted and released the following letter: Dear Fellow Stockholders, With the 37 th Annual J.P. Morgan Healthcare Conference upon us, we wanted to communicate directly with our shareholders.
BOSTON , Dec. 27, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018 , the same day that the broader market and all indexes were up significantly.
BOSTON , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 , at 9 a.m. PST .
-- Joint venture to operate as Eden BioCell -- -- TriArm Therapeutics, a Panacea Venture Healthcare company, to fund Eden BioCell with up to $35M -- -- Ziopharm to license rights of third-generation Sleeping Beauty CD19-specific CAR-T cell therapies to Eden BioCell -- -- Eden BioCell to be owned
BOSTON , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that David Mauney , M.D., has been promoted to President effective immediately. Dr. Mauney, who joined Ziopharm in 2017 as Executive Vice President and Chief Business Officer, will continue to report
Ad-RTS-hIL-12 plus 20mg veledimex (Controlled IL-12) determined to be preferred dosing with low-dose steroids to treat adult patients with recurrent glioblastoma Median overall survival for Ad-RTS-hIL-12 plus veledimex in patients receiving low-dose steroids is 17.8 months Controlled IL-12
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today will host a webcast and conference call today, Nov. 12 , at 8 a.m. ET . On the call, management will discuss recent corporate developments and the new collaboration with Regeneron Pharmaceuticals .
BOSTON , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. , (Nasdaq:ZIOP) today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo ® (cemiplimab-rwlc) to treat
